Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans?

• Status: Completed
• Trial end date: 2019-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Parathyroid (PTH) hormone has been shown to enhance fracture healing in animal studies. There are so far only three published papers concerning humans. Postero-lateral fusions have shown a healing rate of less than 50% after bone. The purpose of this study is to determine if PTH 1-34 (teriparatide) improves the healing rate and the clinical course after spinal stenosis surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Linkoeping
• Collaborator: Medical Research Council of Southeast Sweden
• Treatments: Teriparatide

Criteria

Inclusion Criteria:

• lumbar spinal stenosis operated on with decompression and bone grafting. All ages are accepted, but women must be postmenopausal.

Exclusion Criteria:

• •dementia or psychiatric disorder

• known malignancy < 5 years prior to fracture

• calcium above reference value

• signs of liver disease

• creatinine over ref. value

• inflammatory joint disease

• alcohol or drug abuse

• oral corticosteroid medication

• long-term NSAID-treatment (=> 3 months prior to fracture)